Another new drug has shown promising early results in improving survival for men with advanced prostate cancer. The newest drug showing positive results is called Alpharadin, made by Bayer. Alpharadin is the fourth drug in the past year designed to treat advanced prostate cancer that has shown good early results in improving survival.
Alpharadin, radium-223 chloride, is specifically designed to target prostate cancer which has invaded the bones.
A phase-III clinical trial analyzing Alpharadin showed that, when compared to placebo, there was an increased survival of 3 months in men with advanced prostate cancer. This trial was stopped prematurely due to the positive early results - researchers wanted to give those men randomly assigned to the placebo control group access to the real drug.